Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer
Authors:
- 19 October 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (12) , 1355-1364
Abstract
Background.: Many patients with Gleason 3 + 3 and 3 + 4 early stage prostate cancer receive invasive treatment but likely derive little or no benefit. A novel 8-protein prognostic assay generates a risk score at time of biopsy that is predictive of prostate cancer aggressiveness and can inform treatment decisions. The objective of this study was to evaluate the cost-effectiveness of using the assay to inform treatment decisions compared with usual care.Patients and Methods.: We developed a simulation model to estimate quality-adjusted life-year (QALY) and cost outcomes for the 8-protein assay and usual care strategies. Risk classification outcomes, treatment distributions, costs, health state utilities, and mortality rates were derived from the assay's validation study and the peer-reviewed literature. Outcomes included incremental QALYs, costs, and cost-effectiveness ratios. We conducted one-way and probabilistic sensitivity analyses to evaluate the most influential inputs and to explore joint uncertainty in outcomes, respectively.Results.: The 8-protein assay strategy resulted in 0.04 more QALY and $700 less in costs compared with usual care (and thus was “dominant”). The cost-effectiveness of the assay strategy was most sensitive to the assay cost, the active surveillance health state utility, and the proportion of low-risk patients receiving active surveillance (vs. treatment) in usual care. In the probabilistic sensitivity analyses, the assay strategy decreased cost and increased QALYs in 86.9% and 58.3% of simulations, respectively.Conclusion.: Assuming that ongoing prospective studies support the results of retrospective validation studies, the 8-protein prognostic assay strategy for prostate cancer is likely to be a cost-effective alternative to usual guideline-based care in biopsy Gleason 3 + 3 and 3 + 4 early stage prostate cancer.Keywords
Funding Information
- Metamark Genetics, Inc.
- U.S. Agency for Healthcare Research and Quality (AHRQ 1K12HS022982-01)
This publication has 35 references indexed in Scilit:
- Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysisBJU International, 2012
- The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year AnniversaryJournal of Urology, 2012
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohortBritish Journal of Cancer, 2012
- Lifetime economic burden of prostate cancerBMC Health Services Research, 2011
- Predicting 15-Year Prostate Cancer Specific Mortality After Radical ProstatectomyJournal of Urology, 2011
- Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate CancerJAMA, 2010
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in OncologyJNCI: Journal of the National Cancer Institute, 2010
- Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical ProstatectomyJournal of Clinical Oncology, 2008
- Do Oncologists Believe New Cancer Drugs Offer Good Value?The Oncologist, 2006